Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
10.1 USD +1.30% Intraday chart for Vir Biotechnology, Inc. -0.69% +0.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Vir Biotechnology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule MT
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule CI
Vir Biotechnology's Q4 Loss Widens, Revenue Declines MT
Vir Biotechnology, GSK Terminate Collaboration on Flu DJ
Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M MT
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA CI
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer CI
HC Wainwright Adjusts Vir Biotechnology Price Target to $110 From $85, Maintains Buy Rating MT
North American Morning Briefing : Microsoft Kicks -2- DJ
JPMorgan Downgrades Vir Biotechnology to Neutral From Overweight, Cuts Price Target to $9 From $23 MT
Transcript : Vir Biotechnology, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Vir Biotechnology to Eliminate Roles, Close Facilities to Cut Costs MT
Vir Biotechnology to cut about 75 jobs, shut some facilities RE
Transcript : Vir Biotechnology, Inc. - Special Call
Transcript : Vir Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (VIR) VIR BIOTECHNOLOGY Posts Q3 Revenue $2.6M, vs. Street Est of $8.8M MT
Vir Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer CI
Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD?s the Liver Meeting® 2023 CI
Vir Biotechnology Gets $50 Million in US Government Funding to Support Antibody Platform Technologies Development MT
Biomedical Advanced Research and Development Authority Awards Funding to Vir Biotechnology, Inc. to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats CI
Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV CI
Chart Vir Biotechnology, Inc.
More charts
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its clinical development pipeline consists of product candidates targeting hepatitis B virus (HBV), hepatitis delta virus (HDV) and human immunodeficiency virus (HIV). The Company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). Its pipeline includes VIR-2218, VIR-3434, VIR-1388, VIR-7229, VIR-2482, VIR-2981, VIR-8190, and VIR-1949. VIR-2218 is an investigational HBV-targeting siRNA. VIR-1388 is an investigational HIV T cell vaccine based on human cytomegalovirus (HCMV).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.1 USD
Average target price
29.5 USD
Spread / Average Target
+192.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Vir Biotechnology, Inc. - Nasdaq
  4. News Vir Biotechnology, Inc.
  5. Vir Biotechnology : Posts Wider Q1 Loss on Lower Revenue, Cites Grant Timing